Company: GANX
Filing Date: 2025-04-17
Form Type: PRE 14A
Source: 0001558370-25-004958
Chunk: 0

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-17
Form: PRE 14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

| ​                                          | ​ |
| Filed by the Registrant                    | ☒ |
| Filed by a party other than the Registrant | ☐ |

Check the appropriate box:

| ​ | ​                                                                               |
| ☒ | Preliminary Proxy Statement                                                     |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement                                                      |
| ☐ | Definitive Additional Materials                                                 |
| ☐ | Soliciting Material under § 240.14a-12                                          |

GAIN THERAPEUTICS, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply):

| ​ | ​                                                                                                   |
| ☒ | No fee required                                                                                     |
| ☐ | Fee paid previously with preliminary materials                                                      |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

GAIN THERAPEUTICS, INC. 4800 Montgomery Lane, Suite 220 Bethesda, Maryland 20814 NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS To Be Held On June 24, 2025 To the Stockholders of Gain Therapeutics, Inc.: NOTICE IS HEREBY GIVEN that the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Gain Therapeutics, Inc., a Delaware corporation (the “Company”), will be held on Tuesday, June 24, 2025 at 8:30 a.m. Eastern time at the offices of Lowenstein Sandler LLP, 1251 Avenue of the Americas, 17th Floor, New York, New York 10020, for the following purposes:

| 1. | To elect the eight (8) nominees for director named in the accompanying proxy statement (the “Proxy Statement”) to hold office until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified. |

| 3. | To approve an amendment to the Company’s Amended and Rest